Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neurofibromatoses × Imatinib Mesylate × Clear all

Phase

Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Neurofibrosarcoma 1 Neurofibromatoses 1 Nerve Sheath Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Gastrointestinal Stromal Tumors 1

Interventions

Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡